Navigation Links
Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
Date:2/27/2009

CRANBURY, N.J., Feb. 27 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) announced today that the Company has suspended enrollment for the Phase 2 clinical trial of its investigational drug AT2220 (1-deoxynojirimycin HCI) for the treatment of Pompe Disease and that it has received verbal notice from the U.S. Food and Drug Administration (FDA) that the trial is on clinical hold. After evaluation of available data the Company plans to work closely with the FDA and if appropriate will amend the Phase 2 protocol with the objective of restarting the trial as expeditiously as possible.

Amicus initiated the Phase 2 clinical trial of AT2220 in adults with Pompe disease in June, 2008. Based on encouraging safety data from both preclinical and Phase 1 studies, the approved Phase 2 trial protocol involved initial treatment with a high dose of AT2220. Two patients enrolled in the trial experienced self-reported adverse events and subsequently withdrew from the trial. The events were categorized by the site investigator as serious and probably related to treatment with AT2220.

After initial evaluation of the events, Amicus suspended patient enrollment for the Phase 2 trial. In compliance with regulatory requirements and internal standard operating procedures, the two events were reported to the relevant health authorities, including FDA, and in a subsequent discussion with the FDA the trial was placed on clinical hold status pending further evaluation of the events.

John F. Crowley, President and CEO of Amicus commented, "We will work closely with the investigators and the FDA to address these issues, modify the protocol as appropriate, and get the trial back on track as quickly as possible. We are committed to exploring this new therapy for people living with Pompe disease in as safe a manner as possible."
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... --NOWDiagnostics Inc., based in Springdale, Ark. , ... Canada , a move that brings the company ... have greater access to information concerning their health. ... blood-based rapid tests that allow health care providers to ... ailments and diseases. ZBx Corporation, a Toronto ...
(Date:9/1/2015)... , Sept. 1, 2015  Dr. Cindy ... Labs , the cannabis testing subsidiary of DigiPath, Inc. ... Group about the lack of consistency in today,s ... online resource for medical cannabis information, she explained that ... because their lack of uniform requirements makes standardization impossible. ...
(Date:9/1/2015)... 1, 2015   Alpha Imaging LLC , a leading distributor ... announced today that they have been awarded exclusive rights to ... in Michigan.   The new territory supplements Alpha Imaging,s existing Shimadzu sales ... Ohio , Indiana , ... , West Virginia , Delaware ...
Breaking Medicine Technology:NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 3Alpha Imaging Expands Shimadzu Territory 2
... Medical Systems (NYSE: VAR ) today announced that ... N.A. to repurchase $250 million of its common stock under ... revolving credit facility with Bank of America, N.A. to increase ... Under the accelerated repurchase agreement, Varian will pay $250 ...
... Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced ... trial evaluating the safety and pharmacokinetics of dabigatran ... valves.(1) The 12-week study will compare three doses ... 300mg bid) to warfarin in patients with both ...
Cached Medicine Technology:Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 2Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 2Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 4Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 5Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 6Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 7
(Date:9/1/2015)... ... September 01, 2015 , ... Celebrity hairstylist and Beauty Gives Back Art ... Behind the Fashion” on Thursday, Oct. 1, at the La Valencia Hotel. The presentation, ... the collaboration between fashion and professional hair, makeup and nail design. , The ...
(Date:9/1/2015)... ... September 01, 2015 , ... Pharmaceutical ... different malignancies. Some options for cancer treatment are available belonging to various ... approach is necessary for effective treatment. Several molecules have been discovered out ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... Vending Machine,” is still strongly maintaining her firm’s success in the hair care ... In her upcoming city-to-city tour, Ellis will be providing “Look and learn” live ...
(Date:9/1/2015)... ... September 01, 2015 , ... PetPace, the provider of an ... and activity, today announced its integration with leading veterinary Practice Management Software vendor ... hospital Practice Management Software packages in the US. Practice Management Software helps veterinarians ...
(Date:9/1/2015)... , ... September 01, 2015 , ... Zecurion, a leading ... , its groundbreaking new version of endpoint DLP developed specifically for Mac OS. , ... which more than 100 IT and information security professionals had participated. The beta test ...
Breaking Medicine News(10 mins):Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:Zecurion Announces Endpoint Security for Mac 2
... ... Company Provides À la Carte and Packaged Options Including ... Digital Book Uploading and Specialized Radio Media Tour for Sell-Through,“As ... to the fact many authors are opting for self-publishing, but they ...
... ... Group,s In-Home Care team are scheduled to attend the Homewatch CareGivers Franchise ... Schaffner and Amy Carr, along with Travelers Insurance associate Kim Knudson, will ... newly-announced SilverStone Group and Travelers Insurance Workers, Compensation Coverage. , ...
... ... it easy for sales reps to effectively reach decision makers, delivering the right message at ... Salesforce CRM and any Force.com application. , ... Kirkland, WA (PRWEB) May 10, 2010 -- Marketsync, Inc. announced that for nine ...
... ... and health, Fitness4Her is participating with companies nationwide to support National Women’s Health Week by ... women to focus on their health and make it a top priority. , ... (PRWEB) May 10, 2010 -- Fitness4Her is ...
... School of Medicine researchers has discovered that common intestinal ... mice, but that tumorigenesis can be suppressed if the ... The research, said lead author Eyal Raz, MD, a ... an eventual new form of treatment for people with ...
... an appropriate Mother,s Day gift , SUNDAY, May 9 ... might consider giving her a Mother,s Day gift that could ... life, suggests the American Lung Association. , Freedom From Smoking ... day and offers users tools and support that may help ...
Cached Medicine News:Health News:Bookstomarketnow.Com Launches To Provide Publishing, Distribution & Marketing Solutions For The Self-Publishing Author 2Health News:Bookstomarketnow.Com Launches To Provide Publishing, Distribution & Marketing Solutions For The Self-Publishing Author 3Health News:Bookstomarketnow.Com Launches To Provide Publishing, Distribution & Marketing Solutions For The Self-Publishing Author 4Health News:Bookstomarketnow.Com Launches To Provide Publishing, Distribution & Marketing Solutions For The Self-Publishing Author 5Health News:Bookstomarketnow.Com Launches To Provide Publishing, Distribution & Marketing Solutions For The Self-Publishing Author 6Health News:Homewatch CareGivers Show in Colorado is Next for SilverStone Group's In-Home Care Team 2Health News:Homewatch CareGivers Show in Colorado is Next for SilverStone Group's In-Home Care Team 3Health News:Salesforce.com Users Increase Sales and Marketing Communications 320 Percent 2Health News:Salesforce.com Users Increase Sales and Marketing Communications 320 Percent 3Health News:Fitness4Her Joins National Effort To Encourage Women To Make The Pledge For Health 2Health News:Suppressing activity of common intestinal bacteria reduces tumor growth 2
... a whole blood hematology control manufactured specifically ... 120, and the Coulter AcT5diff instruments. The ... white cell differential, positioning the populations within ... systems. The product offers 105-day closed-vial stability ...
... assayed hematology control, offers complete assay values ... with the Coulter GENS, STKS, MAXM and ... stability, 105-day closed-vial stability and is available ... 4.0ml pierceable cap vial is compatible with ...
Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
Diagnosoft HARP is designed for rapid analysis of tagged cardiac MR images using the HARP technology, which is packaged into an intuitive, easy-to-use graphic user interface....
Medicine Products: